The type 2 diabetes therapy market will steadily expand over the 2018-2028 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in the long term. A rich pipeline of novel agents is expected to launch, promoting sustained market growth. However, these novel therapies predominantly represent later-to-market entrants from existing drug classes or novel combination therapies of existing compounds. Among the drug classes expected to undergo the fastest growth are the sodium/glucose cotransporter 2 (SGLT 2) inhibitors—due to the cardiovascular (CV) benefit demonstrated by Jardiance—and the glucagon-like peptide 1 (GLP 1) receptor agonists—due to their efficacy, potential for weight loss, and the CV benefit associated with Victoza and Ozempic. However, these therapies will face major challenges in uptake, including reimbursement hurdles and an increasingly stringent regulatory environment.

QUESTIONS ANSWERED

  • Following Jardiance’s positive CV results, will SGLT 2 inhibitors surpass the dipeptidyl peptidase (DPP) IV inhibitors as the most valuable oral drug class?
  • Boosted by positive CV data, will Victoza continue to lead the GLP 1 receptor agonists in the face of once-weekly agents such as Trulicity and Ozempic?
  • Will investments by the pharmaceutical industry in novel FDCs such as Xultophy and Soliqua reap rewards?
  • What do key opinion leaders think about emerging therapies such as sotagliflozin, ITCA-650, and oral semaglutide?

PRODUCT DESCRIPTION

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • COVID-19
    • Key Findings
      • Type 2 Diabetes - Key Findings - December 2019
    • Key Updates
      • June 2020
      • March 2020
      • December 2019
      • September 2019
      • April 2019
      • March 2019
    • Market Outlook
      • COVID-19: Areas of Potential Forecast Impact
      • Market Outlook
        • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Type 2 Diabetes?
        • What Factors Are Constraining the Market for Type 2 Diabetes?
      • Drug-Class-Specific Trends
        • DPP-IV Inhibitors
        • SGLT-2 Inhibitors
        • GLP-1 Receptor Agonists
        • GLP-1/GIP Receptor Agonists
        • Long-Acting Insulin Analogues
        • Rapid-Acting Insulin Analogues
        • Long-Acting Insulin/GLP-1 Receptor Agonist Fixed-Dose Combinations
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Etiology and Pathophysiology
        • Disease Overview
        • Etiology
        • Pathophysiology
        • Disease Progression
        • Key Pathways and Drug Targets
    • Epidemiology
      • Introduction
        • Key Findings
      • Epidemiology Populations
        • Total Prevalent Cases of Type 2 Diabetes
        • Diagnosed Prevalent Cases of Type 2 Diabetes
        • Drug-Treated Cases of Type 2 Diabetes
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • DPP-IV Inhibitors
        • GLP-1 Receptor Agonists
        • SGLT-2 Inhibitors
        • Biguanides
        • Sulfonylureas
        • Thiazolidinediones
        • Long-Acting Insulins
        • Short- and Intermediate-Acting Insulins
        • Rapid-Acting Insulins
        • Premixed Insulins
        • Long-Acting Insulin/GLP-1 Receptor Agonist Fixed-Dose Combinations
      • Medical Practice
        • Overview
        • Region-Specific Treatment
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Type 2 Diabetes
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments in the Late-Phase Pipeline for Type 2 Diabetes
        • SGLT-2 Inhibitors
        • GLP-1 Receptor Agonists
        • GLP-1/GIP Receptor Agonists
        • AMP-Activated Protein Kinase Stimulators
        • Ultra Rapid-Acting Insulin Analogues
      • Early-Phase Pipeline Analysis
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
        • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Type 2 Diabetes Bibliography

Author(s): David Rees, Ph.D; Joseph Granato, MPH

David Rees, , is a Business Insights Analyst with the Cardiovascular, Metabolic, and Renal Disorders team at Decision Resources Group. Prior to joining Decision Resources Group, Dr. Rees was a Postdoctoral Research Associate at Imperial College London, and the Institute of Cancer Research. For his doctoral research, he studied the structures of molecular machines in the Nobel Prize winning laboratory of Prof. Sir John Walker at the University of Cambridge. Dr. Rees earned his undergraduate from the University of Bath.

Joseph Granato joined Decision Resources Group in 2012 and previously worked on both Market Access and Global Market Access ; Joseph is currently responsible for forecasting the prevalence and incidence of disease populations throughout the ; He is also tasked with identifying at risk populations and developing new epidemiological methods used to predict overall population health. He received his from Des Moines University where he worked on several population health projects including the delivery of continuing medical education on tick-borne ; He also holds a in Animal Science from the University of ; Prior to his time with DRG Joseph worked with the Monroe County Health Department on the surveillance of reportable diseases including Dengue Fever.


Related Reports

Type 2 Diabetes | Unmet Need | Detailed, Expanded Analysis (US/EU)

The type 2 diabetes (T2D) drug market is expected to expand, fueled by a rich pipeline of agents. However, growth will be tempered because these emerging ther...

View Details

Type 2 Diabetes | Access & Reimbursement | Detailed, Expanded Analysis (US)

The treatment of type 2 diabetes places a significant economic burden on the U.S. healthcare system. Given the intense competition between antidiabetic therapies, the type 2 diabetes access and r...

View Details

Type 2 Diabetes | Geographic Focus: China | Type 2 Diabetes | China In-Depth | China

Type 2 diabetes (T2D) is one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Traditional therapies such as...

View Details

Type 2 Diabetes | Unmet Need | Detailed, Expanded Analysis: Injectables (US/EU)

The type 2 diabetes (T2D) therapy market is expected to expand, fueled by a rich pipeline of agents. However, growth will be tempered because these emerging therapies will be predominantly later-...

View Details